This article summarizes the most significant insider buying and selling activities reported for Monday, November 25, 2024, in US stocks.
Top Buys:
Neurogene Inc. (NASDAQ:NGNE): Christine Mikail, President and CFO of Neurogene Inc., acquired 24,000 shares of the company's common stock on November 22, 2024. The purchase, valued at approximately $491,400, was made at a weighted average price of $20.475 per share. This acquisition brings Mikail's total holdings to 76,844 shares, some jointly owned with her spouse. Neurogene, a pharmaceutical preparations company, has recently reported promising low-dose efficacy data for its Rett syndrome treatment, NGN-401, despite facing challenges with a high-dose patient. The company has also secured significant PIPE financing to support ongoing trials.
Neurogene Inc. (NASDAQ:NGNE): Rachel McMinn, Chief Executive Officer of Neurogene Inc., purchased 47,500 shares of the company's common stock on November 22, 2024. The acquisition, valued at approximately $968,999, was made at a weighted average price of $20.40 per share. Following this purchase, McMinn now holds a total of 1,297,859 shares in Neurogene. This insider buy comes as the company continues to advance its investigational therapy for Rett syndrome, NGN-401, supported by recently secured PIPE financing.
Ventyx Biosciences, Inc. (NASDAQ:VTYX): Mohan Raju, CEO and President of Ventyx Biosciences, Inc., acquired a substantial 500,000 shares of the company's common stock over two transactions on November 22 and November 25, 2024. The purchases were made at prices ranging from $1.74 to $2.10 per share, totaling approximately $959,889. This significant investment by the company's top executive increased Raju's direct ownership to 2,175,028 shares.
Modular Medical (TASE:PMCN), Inc. (NASDAQ:MODD): Manchester Management Co LLC, led by CEO James E. Besser, acquired 166,666 shares of Modular Medical, Inc.'s common stock at $1.50 per share, totaling approximately $249,999. This purchase increases Manchester Management's stake to over 3.28 million shares. The transaction coincides with recent developments at Modular Medical, including the securing of a U.S. patent for its MODD1 insulin pump and FDA clearance for the device's use in adults.
Top Sells:
Innodata Inc. (NASDAQ:INOD): Jack Abuhoff, CEO and President of Innodata Inc., sold 466,775 shares of the company's common stock on November 22 and 25, 2024. The sales, executed at prices ranging from $44.60 to $48.00 per share, totaled approximately $25.56 million. Concurrently, Abuhoff acquired 555,000 shares through stock option exercises. These transactions were part of Abuhoff's long-term financial planning strategy.
Abacus Life, Inc. (NASDAQ:ABL): Jay J. Jackson, CEO of Abacus Life, Inc., sold 2,031,250 shares of common stock on November 21, 2024, at $8 per share, totaling $16.25 million. Approximately 1,875,000 of these shares were sold to cover taxes associated with vesting restricted stock. This sale comes amid positive analyst sentiment towards Abacus Life, with recent price target increases from B.Riley and Piper Sandler.
Snowflake Inc . (NYSE:NYSE:SNOW): Benoit Dageville, President of Products at Snowflake Inc., sold 137,500 shares of Class A Common Stock over two days, at prices between $161.50 and $175 per share. The total value of these transactions amounted to approximately $23.1 million. These sales were part of a pre-arranged 10b5-1 trading plan adopted earlier in the year.
Confluent , Inc. (NASDAQ:CFLT): Matthew Craig Miller, a director at Confluent, Inc., executed multiple sales of the company's Class A Common Stock between November 21 and November 25, 2024. The combined transactions totaled over 1.2 million shares, generating proceeds of approximately $38.78 million.
Astera Labs, Inc. (NASDAQ:ALAB): Mohan Jitendra, CEO of Astera Labs, Inc., sold 171,064 shares of common stock on November 21, 2024, at an average price of $103.53, totaling approximately $17.7 million. These sales were executed through various trusts as part of a pre-established Rule 10b5-1 trading plan.
Investors should stay informed about insider buying and selling activities as they can provide valuable insights into a company's internal perspective. While insider transactions alone should not be the sole basis for investment decisions, they can be an important factor to consider alongside other financial and market data when evaluating potential investment opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.